Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study

Journal of Viral Hepatitis

Volumn 25, Issue 5, 2018, Pages 457-464

  Brown, A ^a   Hezode C ^b   Zuckerman, E ^c   Foster, G R ^d   Zekry, A ^e   Roberts, S K ^f   Lahser, F ^g   Durkan, C ^g   Badshah, C ^g   Zhang, B ^g   Robertson, M ^g   Wahl, J ^g   Barr, E ^g   Haber, B ^g  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b HENRI MONDOR HOSPITAL   (France)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f ALFRED HOSPITAL   (Australia)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

clinical trial; elbasvir; grazoprevir; hepatitis; ribavirin

Indexed keywords

ELBASVIR; GRAZOPREVIR; RIBAVIRIN; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; MK-5172; QUINOXALINE DERIVATIVE;

ADULT; ARTICLE; ASTHENIA; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; ADVERSE DRUG REACTION; AGED; CHRONIC HEPATITIS C; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; ISOLATION AND PURIFICATION; PHASE 2 CLINICAL TRIAL; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZOFURANS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; QUINOXALINES; RIBAVIRIN; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85043693827     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12801     Document Type: Article

References (20)

1. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932-954.
2. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199-236.
3. Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection: ELECTRON-1. Presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7-11, 2014; Boston, MA.
4. Kapoor R, Kohli A, Sidharthan S. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology. 2014;60(1 Suppl):321A.
5. Abergel A, Loustaud-Ratti V, Metivier S, et al. Ledipasvir/sofosbuvir results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. J Hepatol. 2015;62(Suppl 2):S219-S220.
6. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-1887.
7. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867-1877.
8. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993-2001.
9. Dieterich D, Bacon B, Flamm SL. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology. 2014;60(1 Suppl):220A.
10. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211-221.
11. Foster GR, Pianko S, Cooper C, et al. Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study. J Hepatol. 2015;62(Suppl. 2):S259-S260.
12. Merck & Co., Inc. Zepatier (elbasvir and grazoprevir) tablets, for oral use. Prescribing Information. https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. Accessed November 13, 2017.
13. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1-13.
14. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319-e327.
15. Kwo P, Gane E, Peng C-Y, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152:164-175.e4.
16. Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63:564-572.
17. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537-1545.
18. Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56:4161-4167.
19. Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013;8:1930-1940.
20. Asante-Appiah E, Curry S, McMonagle P, et al. Antiviral activity and resistance analysis of NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in hepatitis C virus GT4 replicons. Antimicrob Agents Chemother. 2017;61: pii: e00363-17.